Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNew Valley University

About this trial

Antiphospholipid syndrome is a thrombo-inflammatory autoimmune disorder with a complex antiphospholipid antibody-mediated pathogenesis, and high heterogeneity in clinical presentation and disease course. Clinical presentation in antiphospholipid syndrome includes venous and arterial thrombosis, pregnancy complications, and a broad range of microvascular and non-thrombotic manifestations

Eligibility criteria

Qualifiers

Adults (age ≥18 years)

Diagnosis of APS based on updated Sydney classification criteria confirmed by: Clinical history of thrombosis and/or pregnancy morbidity, Persistent presence (≥12 weeks) of antiphospholipid antibodies (aCL, anti-β2-glycoprotein I, and/or lupus anticoagulant)

Disqualifiers

Current infection or inflammatory condition unrelated to APS

Hematological malignancies or other blood disorders

Recent blood transfusion or platelet-altering medications other than APS treatments

Trial design

Treatments tested in this trial

  • • Complete blood count , MPV
  • Calculation of PLR: Platelet count / Lymphocyte count and Calculation of NLR:
  • Antiphospholipid antibody profile

Treatment groups

150 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators